Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design.

× No keyword cloud information.

15 in total

1. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation.

Authors: E C Marshburn; M G Aman
Journal: J Autism Dev Disord Date: 1992-09

2. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.

Authors: S H Willemsen-Swinkels; J K Buitelaar; H van Engeland
Journal: Biol Psychiatry Date: 1996-06-15 Impact factor: 13.382

3. A comparison between the handicaps behaviour and skills schedule and the psychoeducational profile.

Authors: I van Berckelaer-Onnes; G van Duijn
Journal: J Autism Dev Disord Date: 1993-06

4. Naltrexone in young autistic children: replication study and learning measures.

Authors: B K Kolmen; H M Feldman; B L Handen; J E Janosky
Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-11 Impact factor: 8.829

5. The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial.

Authors: J K Buitelaar; H van Engeland; K de Kogel; H de Vries; J van Hooff; J van Ree
Journal: J Am Acad Child Adolesc Psychiatry Date: 1992-11 Impact factor: 8.829

6. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.

Authors: B K Kolmen; H M Feldman; B L Handen; J E Janosky
Journal: J Am Acad Child Adolesc Psychiatry Date: 1995-02 Impact factor: 8.829

7. Placebo-controlled acute dosage naltrexone study in young autistic children.

Authors: S H Willemsen-Swinkels; J K Buitelaar; F G Weijnen; H van Engeland
Journal: Psychiatry Res Date: 1995-10-16 Impact factor: 3.222

8. Naltrexone in autistic children: behavioral symptoms and attentional learning.

Authors: M Campbell; L T Anderson; A M Small; P Adams; N M Gonzalez; M Ernst
Journal: J Am Acad Child Adolesc Psychiatry Date: 1993-11 Impact factor: 8.829

9. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

Authors: M G Aman; N N Singh; A W Stewart; C J Field
Journal: Am J Ment Defic Date: 1985-03

10. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.

Authors: S H Willemsen-Swinkels; J K Buitelaar; G J Nijhof; H van England
Journal: Arch Gen Psychiatry Date: 1995-09

6 in total

1. Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management.

Authors: P G Williams; A Allard; L Sears; N Dalrymple; A S Bloom
Journal: J Autism Dev Disord Date: 2001-02

Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design.

1. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation.

2. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.

3. A comparison between the handicaps behaviour and skills schedule and the psychoeducational profile.

4. Naltrexone in young autistic children: replication study and learning measures.

5. The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial.

6. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.

7. Placebo-controlled acute dosage naltrexone study in young autistic children.

8. Naltrexone in autistic children: behavioral symptoms and attentional learning.

9. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

10. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.

1. Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management.

Review 2. Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Review 3. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.

Review 4. Medication treatment in subjects with autistic spectrum disorders.

5. The role of proopiomelanocortin (POMC) in sequentially dependent self-injurious behavior.

Review 6. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.